La tétracycline, connue sous le nom commercial Sumycin, agit en bloquant la fixation de l’ARNt sur la sous-unité 30S ribosomale, interrompant l’élongation de la chaîne protéique bactérienne. Ce mécanisme confère une activité sur un spectre large, incluant bactéries Gram positives, Gram négatives, rickettsies et spirochètes. Sa biodisponibilité digestive varie selon la prise alimentaire et les interactions avec les ions divalents comme calcium et magnésium. Sa diffusion tissulaire est importante, notamment dans les voies respiratoires et génito-urinaires. L’élimination se fait par voie rénale et biliaire. Les effets indésirables incluent photosensibilisation, troubles digestifs et coloration dentaire en cas d’administration précoce. Les guides thérapeutiques mentionnent sumycin prix, en soulignant la nécessité de restreindre son utilisation afin de limiter les résistances acquises.

C:\documents and settings\administrator\my documents\giannini\notes&memos\questionnaire.wpd

LAW OFFICES OF PATRICK E. CATALANO
A PROFESSIONAL CORPORATION
SAN DIEGO OFFICE
SAN FRANCISCO OFFICE
The Koll Center
781 Beach Street, Suite 333
501 West Broadway, Suite 740
San Francisco, California 94109
San Diego, California 92101-3544
(415) 788-0207
(619) 233-3565
Fax: (415) 447-0066
Fax: (619) 233-9841
Charles S. LiMandri, Esq.
Nicholas A. Siciliano, Esq.
LAW OFFICES OF CHARLES S. LiMANDRI
LAW OFFICES OF MASRY & VITITOE
P.O. Box 9120
A Professional Corporation
16236 San Dieguito Road
5707 Corsa Avenue, Second Floor
Building 3, Suite 3-15
Westlake Village, California 91362
Rancho Santa Fe, California 92067
(818) 991-8900
(858) 759-9930
Fax: (818) 991-6200
Fax: (858) 759-9938
CLIENT QUESTIONNAIRE
Ann Giannini, et. al. v. Schering-Plough, et. al.
Client Name:______________________________________________________________ Date of diagnosis of Hepatitis C:__________________________________________ Genotype:____________________________________________________________ Viral Load (if known):__________________________________________________ Severity and type of Hepatitis C symptoms (mild, moderate, severe) prior totreatment:__________________________________________________________ _________________________________________________________________________ Other medical conditions at the time of diagnosis:___________________________ _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ Who suggested PEG-Intron and/or Rebetol treatment?_________________________ _________________________________________________________________________ Was Schering-Plough the manufacturer of the PEG-Intron and/or Rebetolused?______________________________________________________________ Client QuestionnairePage 2_______________________ Did your physician describe the potential risks and benefits of this therapy? say?_____________________________________________ _________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ Did your physician describe the types of serious reactions you might experience? If yes, what were these adverse reactions?___________________________________ _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ Date PEG-Intron and/or Rebetol therapy started:______________________________ Where was the PEG-Intron and/or Rebetol obtained? Please state the name, addressand telephone number of the pharmacy:____________________________________ _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ ___________________________________________________________________________ Do you have any paperwork regarding the order of PEG-Intron and/or Rebetol? Ifyes, please attach.
Were you told to wait to begin therapy until a new form of Intron was available fortreatment?__________________________________________________________ If yes, how long did you wait?__________________________________________ __________________________________________________________________________ Date PEG-Intron and/or Rebetol therapy stopped:_____________________________ Was Rebetol (ribavirin) also prescribed and if so what was the dosage?___________ __________________________________________________________________________ Client QuestionnairePage 3_______________________ Please list other medications taken at the same time:___________________________ __________________________________________________________________________ __________________________________________________________________________ Dat e o f f i r s t a d v e r s e re a c t i on t o PEG- I n t ron and/or Rebetol:____________________________________________________________ How long were you treated before your adverse reactions started?_______________ __________________________________________________________________________ ___________________________________________________________________________ Please list the adverse reactions and note their severity:________________________ __________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ __________________________________________________________________________ ___________________________________________________________________________ ___________________________________________________________________________ _________________________________________________________________________ Do you still have these adverse reactions?__________________________________ __________________________________________________________________________ Have these adverse reactions become less or more severe?______________________ __________________________________________________________________________ Are these adverse reactions disabling?_____________________________________ _________________________________________________________________________ Were you hospitalized because of these adverse reactions?_____________________ __________________________________________________________________________ Client QuestionnairePage 4_______________________ Why do you think PEG-Intron and/or Rebetol caused these symptoms?____________ __________________________________________________________________________ ___________________________________________________________________________ _________________________________________________________________________ ___________________________________________________________________________ __________________________________________________________________________ __________________________________________________________________________ __________________________________________________________________________ Did your physician adjust your dose or discontinue treatment after you reported thesesymptoms to him/her?___________________________________________________ __________________________________________________________________________ Did you report the adverse reactions(s) to the drug company and, if so, which drugcompany (name, address, telephone number)?________________________________ __________________________________________________________________________ ___________________________________________________________________________ ___________________________________________________________________________ If yes, how did the drug company respond?__________________________________ ___________________________________________________________________________ __________________________________________________________________________ __________________________________________________________________________ __________________________________________________________________________ Did you report the adverse reaction(s) to the FDA or to anyone else and, if so, pleaselist in detail:__________________________________________________________ __________________________________________________________________________ ___________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ _________________________________________________________________________ __________________________________________________________________________ Client QuestionnairePage 5_______________________ Do you know the lot numbers of any of the PEG-Intron and/or Rebetol or ribavirintreatments you took and, if so, please list:__________________________________ _________________________________________________________________________ _________________________________________________________________________ How did you obtain your Intron or PEG-Intron and/or Rebetoldrug?_______________________________________________________ _________________________________________________________________________ ___________________________________________________________________________ Identify by batch and lot number the PEG-Intron and/or Rebetolused?______________________________________________________________ __________________________________________________________________________

Source: http://hepatitiscfree.com/pdf/Suit-questionnaire.pdf